Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

533
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
533
Cancer Survival Analysis01:21

Cancer Survival Analysis

629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

536
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
536
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

382
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
382
Actuarial Approach01:20

Actuarial Approach

276
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
276
Censoring Survival Data01:09

Censoring Survival Data

502
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Leukemia·2026
Same author

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Health-related quality of life reporting in randomized controlled trials of chimeric antigen receptor T-cell therapy: A systematic review of dedicated publications.

British journal of haematology·2026
Same author

Cancer chemo-immunotherapy: time will tell.

Cancer immunology research·2026
Same author

[211At]Astatine-Based Conditioning with a Humanized CD45 Antibody for Autologous Hematopoietic Stem Cell Gene Therapy.

Blood·2026

Related Experiment Video

Updated: Jan 8, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

Detecting the Cure Model Appropriateness in Randomized Clinical Trials With Long-Term Survivors.

Cheryl Kouadio1,2,3, Subodh Selukar4, Megan Othus5

  • 1INSERM U1342, Team ECSTRRA, Hôpital Saint Louis, Paris, France.

JCO Clinical Cancer Informatics
|December 15, 2025
PubMed
Summary

The cure model is appropriate for analyzing survival data in randomized clinical trials (RCTs) with long-term survivors. The ratio estimation of censored cured subjects (RECeUS) method, applied separately to each arm, helps confirm the presence of cured patients.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

625
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

625
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.2K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Survival Analysis

Background:

  • Analyzing right-censored endpoints in randomized clinical trials (RCTs) with long-term survivors presents challenges.
  • The presence of long-term survivors may indicate a 'cured' fraction within the patient population.
  • Traditional survival models may not adequately capture the dynamics of cure in such scenarios.

Purpose of the Study:

  • To evaluate the suitability of cure models for analyzing right-censored endpoints in malignancy RCTs with long-term survivors.
  • To extend the ratio estimation of censored cured subjects (RECeUS) method for application in RCTs.

Main Methods:

  • Four decision rules based on the RECeUS method were developed to assess cure model appropriateness in RCTs.
  • A simulation study evaluated the performance of these rules and the impact of link functions.
  • The proposed method was illustrated using real-world data from RCTs in acute leukemia and COVID-19.

Main Results:

  • Simulation results indicated that applying the RECeUS criteria to at least one randomized arm is the most robust decision rule across various treatment effect scenarios.
  • The cure model was found to be appropriate for the analyzed RCT data, irrespective of the specific decision rule employed.
  • The RECeUS method demonstrated utility in confirming the presence of cured patients in RCT settings.

Conclusions:

  • A plateau in survival curves within RCTs suggests the potential appropriateness of a cure model.
  • The RECeUS method should be applied to each randomized arm independently to validate the presence of a cured population.
  • Meeting the RECeUS criteria in at least one randomized arm supports the use of a cure model in RCT survival analysis.